OpenEvidence Secures $1 Billion Valuation in Sequoia-Led Funding Round, Partners with NEJM

OpenEvidence Achieves Unicorn Status with $75 Million Series A Funding

OpenEvidence, a rapidly growing AI-powered platform for doctors, has secured a $75 million Series A funding round led by Sequoia Capital, catapulting the company to a $1 billion valuation 1

1

3

3

. This milestone marks OpenEvidence's first institutional investment and brings its total capital raised to over $100 million 1

1

2

2

.

Revolutionary AI Copilot for Medical Professionals

Founded by Daniel Nadler, OpenEvidence aims to organize and expand the world's collective medical knowledge by offering a groundbreaking AI copilot for doctors 1

1

. The platform assists medical professionals in making critical decisions at the point of care, leveraging specialized content from strategic partnerships, including the New England Journal of Medicine (NEJM) 2

2

.

Rapid Adoption and User Base Growth

Since its launch in 2023, OpenEvidence has experienced unprecedented growth, becoming the fastest-growing platform for doctors in history 1

1

. The company reports:

• Hundreds of thousands of verified doctors using the platform daily
• Presence in over 10,000 care centers across the United States
• 40,000 new verified U.S. doctors and healthcare providers registering monthly
• 75% of users leveraging OpenEvidence during office hours for clinical decision support 2

  2

Strategic Partnership with NEJM Group

Alongside the funding announcement, OpenEvidence revealed a multi-year content agreement with NEJM Group, publisher of the New England Journal of Medicine 1

1

. This partnership will provide OpenEvidence access to published content and multimedia from 1990 onwards from various NEJM publications, enhancing the platform's knowledge base 2

2

.

Future Plans and Industry Impact

OpenEvidence plans to utilize the new funding to:

1. Train next-generation medical domain-specialized Large Language Models (LLMs)
2. Expand its team of AI scientists and medical researchers
3. Forge additional strategic content partnerships
4. Develop its own library of advanced medical knowledge 1

   1

   3

   3

Pat Grady, partner at Sequoia Capital, emphasized the potential impact of OpenEvidence, stating, "The scale of OpenEvidence's life-saving impact is massive, positioning it to become one of the most important companies of the next decade" 2

2

.

Addressing Healthcare Challenges

With medical knowledge doubling every 73 days, OpenEvidence aims to empower doctors to stay current with the rapid pace of change in the medical field 2

2

. The platform's adoption comes at a crucial time, as the U.S. is projected to face a shortage of almost 100,000 physicians by the end of the decade 4

4

.

Unique Approach to AI in Healthcare

Unlike general-purpose AI chatbots, OpenEvidence is built specifically for medical professionals and trained on high-quality, peer-reviewed medical content 3

3

. This focused approach helps the platform avoid issues like "hallucinations" that can plague AI systems trained on less reliable data sources 4

4

.

As the healthcare industry continues to grapple with increasing demands and rapid advancements, OpenEvidence's AI-driven solution presents a promising tool to support medical professionals in delivering informed and efficient patient care.